Biocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management drug. Biocon aims to become a global medicines company driven by innovation. Insulin remains a strategic anchor. Oncolo…
Mumbai: Biocon will hold off on a near-term launch of semaglutide in India, where the market for the generic versions of Novo Nordisks diabetes and anti-obesity drug is already crowded, its incoming … [+3752 chars]
